FAIM
PACB icon

Financial Advocates Investment Management’s Pacific Biosciences PACB Stock Holding History

Financial Advocates Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$49.6K – 418
2025
Q2 		$49.6K Buy
+40,000
New +$46.2K ﹤0.01% 614

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Financial Advocates Investment Management's PACB Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 40,000 shares — an estimated $49.6K sold.

Financial Advocates Investment Management first reported a position in PACB in Q2 2025 and held it in 1 quarter. The position peaked at $49.6K in Q2 2025. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Financial Advocates Investment Management reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 40,000 Pacific Biosciences shares in Q3 2025, an estimated $49.6K.
  • Financial Advocates Investment Management first reported a position in Pacific Biosciences in Q2 2025 and held it in 1 quarter.
  • Financial Advocates Investment Management's Pacific Biosciences position peaked at $49.6K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.